Vindesine and Prednisone in the Treatment of Relapsed Lymphomalignancies, Blastic Crisis of Chronic Myelocytic Leukemia and Acute Myelomonocytic Leukemia

Hulhoven, R.; Michaux, Jean Louis; Cornu, Guy; Ferrant, A; Symann, Michel; Bosly, A; Delannoy, André; Dutrieux-Fauchet, M. C.; Sokal, G.

doi:10.1159/000428626

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been six complete and 32 partial responses to vindesine (42%) among 91 heavily pretreated patients with non-Hodgkin's lymphomas.loI 14,15,33,[35][36][37] Miller observed response rates of 41 % among patients with a history of vincristine therapy and 33% among those who had received vinb l a~t i n e .~~ Mathe reported a 43% response rate among seven vincristine resistant patients.12 Response durations were usually brief; however, some patients have achieved responses lasting nearly two years.loO 32* 36, 37 The usual vindesine dose was 3 mg/ M2/week by intravenous injection.…”

Section: Non-hodgkin 'S Lymphomamentioning

confidence: 99%

Pharmacology, Clinical Efficacy and Adverse Effects of Vindesine Sulfate, A New Vinca Alkaloid

et al. 1983

View full text Add to dashboard Cite

Vindesine is a new vinca alkaloid antineoplastic agent derived from vinblastine. However, its antineoplastic spectrum more closely resembles that of vincristine. Clinical studies indicate activity against acute leukemia, lung cancer, carcinoma of the breast, squamous cell carcinoma of the esophagus and head and neck, Hodgkin's disease and non-Hodgkin's lymphomas. Pharmacokinetic studies indicate that vindesine exhibits a triphasic elimination pattern with a terminal half-life of 24.2 hours. Elimination is primarily through hepatic metabolism. The major side effects associated with vindesine therapy are myelosuppression and neurotoxicity. Other side effects include alopecia, nausea and vomiting and local tissue irritation associated with extravasation. Vindesine will be a positive addition to the antineoplastic armamentarium. The full extent of its activity remains to be established.

show abstract

Section: Non-hodgkin 'S Lymphomamentioning

confidence: 99%

Pharmacology, Clinical Efficacy and Adverse Effects of Vindesine Sulfate, A New Vinca Alkaloid

et al. 1983

View full text Add to dashboard Cite

show abstract

The treatment of chronic myelogenous leukemia in blastic crisis with the chemotherapy incorporating vindesine-prednisolone.

Saito

Uzuka

Takahashi

et al. 1986

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Twenty-three patients with chronic myelogenous leukemia (CML) in terminal transformation were teated with regimen incorporating vindesine and prednisolone with or without cytosine arabinoside. Twenty-one patients in blastic crisis (BC) were classified into subgroups on the blast cell morphology. Of these 21 patients, 5 (23.8%) had lymphoid morphology, 12 (57.2%) had myeloid morphology, and 4 (19.0%) had monocytoid morphology. All of five patients with lymphoid morphology and ten of twelve patients with myeloid morphology achieved complete remission (83.3° ), while none of four patients with monocytoid morphology achieved complete remission. Two patients in accelerated phase also attained complete remission. Our results indicate that the regimens incorporating vindesine and prednisolone with or without cytosine arabinoside should be the treatment of choice in CML-BC both lymphoid and myeloid morphology and accelerated phase of CML as well, chronic myelogenous leukemia in blastic crisis ; therapy ; cell morphology

show abstract

Vindesine and Prednisone in the Treatment of Relapsed Lymphomalignancies, Blastic Crisis of Chronic Myelocytic Leukemia and Acute Myelomonocytic Leukemia

Cited by 2 publications

References 0 publications

Pharmacology, Clinical Efficacy and Adverse Effects of Vindesine Sulfate, A New Vinca Alkaloid

Pharmacology, Clinical Efficacy and Adverse Effects of Vindesine Sulfate, A New Vinca Alkaloid

The treatment of chronic myelogenous leukemia in blastic crisis with the chemotherapy incorporating vindesine-prednisolone.

Contact Info

Product

Resources

About